信迪利单抗注射液联合 SOX 方案新辅助治疗局部进展期胃癌的 临床研究.

Objective: To observe the clinical efficacy of xindili monoclonal antibody injection combined with S-1 and oxaliplatin (SOX) regimen as neoadjuvant therapy for locally advanced gastric cancer. Methods: According to the random number table method, 98 patients with locally advanced gastric cancer received in Xuzhou Cancer Hospital from January 2022 to June 2023 were divided into control group (49 cases treated with SOX regimen) and study group (49 cases treated with xindili monoclonal antibody injection on the basis of control group). The efficacy [objective response rate (ORR), disease control rate (DCR)], serum tumor marker levels, T lymphocyte subsets and incidence of adverse reactions were compared between two groups. Results: In study group, the ORR and DCR were higher than those in control group (P<0.05). After treatment, CEA, CA724, CA125 and CD8+ in study group were lower than those in control group, CD4+ and CD4+/CD8+ were higher than those in control group(P<0.05). The incidence of adverse reactions in the study group was 32.65% higher than that in the control group, which was 28.57%, but there was no difference between the two groups (P>0.05). Conclusion: Xindili monoclonal antibody injection combined with SOX regimen neoadjuvant therapy for locally advanced gastric cancer, which can effectively prevent disease progression, reduce serum tumor marker levels, improve immune function. [ABSTRACT FROM AUTHOR]